This site is intended for health professionals only

Covid booster programme expanded to all over-18s

by Sofia Lind
29 November 2021

Share this article

The JCVI has recommended that the Covid booster jab campaign should be expanded to all over-18s in response to the Omicron variant.

It also recommended that a booster dose can be given three months after completion of the initial course of vaccination – a reduction from previous guidance of six months.

Further, 12 to 15-year-olds should have their second dose of Covid vaccine 12 weeks after their first dose, the JCVI added.

And patients who are immunosuppressed should be offered a booster dose, three months after their third jab, which had completed their initial vaccination course.

The JCVI said that the intention of the measures is ‘to accelerate the deployment of Covid-19 vaccines before the peak of any impending Omicron wave’.

But they added that this comes as there ‘is currently no data to indicate that Omicron infection is associated with a change in the pattern of susceptibility to serious Covid-19 (hospitalisation and death)’.

Boosters should continue to be prioritised for persons of older age, or who are in Covid-19 at-risk groups, as these ‘are likely to remain at higher risk from serious Covid-19’.

Pfizer and Moderna vaccines continue to be recommended for the booster dose, although anyone unable to have the mRNA vaccines can have an AstraZeneca jab instead.

The announcement comes just weeks after the booster campaign was expanded to include over-40s, in addition to vulnerable and older adults.

New JCVI advice in full:

JCVI advises the following immediate measures within the Covid-19 vaccine programmes:

  1. Booster vaccination eligibility should be expanded to include all adults aged 18 years to 39 years.
  2. Booster vaccination should now be offered in order of descending age groups, with priority given to the vaccination of older adults and those in a Covid-19 at-risk group. Booster vaccination should not be given within 3 months of completion of the primary course.
  3. Severely immunosuppressed individuals who have completed their primary course (3 doses) should be offered a booster dose with a minimum of 3 months between the third primary and booster dose. Those who have not yet received their third dose may be given the third dose now to avoid further delay. A further booster dose can be given in 3 months, in line with the clinical advice on optimal timing.
  4. Both the Moderna (50 microgram) and Pfizer-BioNTech (30 microgram) vaccines should be used with equal preference in the Covid-19 booster programme. Both vaccines have been shown to substantially increase antibody levels when offered as a booster dose.

In addition, JCVI advises the following secondary measure, subject to appropriate consideration by deployment teams regarding feasibility.

All children and young people aged 12 to 15 years should be offered a second dose (30 micrograms) of the Pfizer-BioNTech Covid-19 vaccine at a minimum of 12 weeks from the first dose. The interval between vaccines may be reduced to at least 8 weeks between doses if the emerging epidemiological data supports this (and those aged 16 to 17 may also be offered their second dose with an interval of at least 8 weeks).

Source: JCVI

This story was initially published on our sister title Pulse.